U.S. Markets close in 3 hrs 3 mins

Celsion conducts comprehensive analysis of data from Phase III Heat study

Emerging data from the HEAT Study post analysis demonstrates that ThermoDox markedly improves progression free survival and overall survival in patients who had optimal RFA. The analysis indicates that if patients' lesions undergo RFA for 45 minutes or more, they clearly benefitted from ThermoDox(R). These findings apply to HCC lesions from both size cohorts of the HEAT Study and represent a sizable subgroup of patients. This data is subject to further verification and review by the HEAT Study Steering Committee.